| Literature DB >> 29416677 |
Jialiang Yang1, Yufang Qin2, Tiantian Zhang1, Fayou Wang3, Lihong Peng1, Lijuan Zhu4, Dawei Yuan5, Pan Gao6, Jujuan Zhuang6, Zhongyang Zhang7,8, Jun Wang9, Yun Fang9.
Abstract
Aging is a major risk factor for age-related diseases such as certain cancers. In this study, we developed Age Associated Gene Co-expression Identifier (AAGCI), a liquid association based method to infer age-associated gene co-expressions at thousands of biological processes and pathways across 9 human tissues. Several hundred to thousands of gene pairs were inferred to be age co-expressed across different tissues, the genes involved in which are significantly enriched in functions like immunity, ATP binding, DNA damage, and many cancer pathways. The age co-expressed genes are significantly overlapped with aging genes curated in the GenAge database across all 9 tissues, suggesting a tissue-wide correlation between age-associated genes and co-expressions. Interestingly, age-associated gene co-expressions are significantly different from gene co-expressions identified through correlation analysis, indicating that aging might only contribute to a small portion of gene co-expressions. Moreover, the key driver analysis identified biologically meaningful genes in important function modules. For example, IGF1, ERBB2, TP53 and STAT5A were inferred to be key genes driving age co-expressed genes in the network module associated with function "T cell proliferation". Finally, we prioritized a few anti-aging drugs such as metformin based on an enrichment analysis between age co-expressed genes and drug signatures from a recent study. The predicted drugs were partially validated by literature mining and can be readily used to generate hypothesis for further experimental validations.Entities:
Keywords: GTEx; aging; anti-aging drug prediction; gene co-expression; liquid association
Year: 2017 PMID: 29416677 PMCID: PMC5787419 DOI: 10.18632/oncotarget.23148
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1(A–D) An overview of the AAGCI algorithm.
Top 20 most frequent age-associated gene co-expressions for modules defined by GO terms in adipose
| Gene 1 | Gene 2 | Occurrence* | Gene 1 | Gene 2 | Occurrence |
|---|---|---|---|---|---|
| 37 | 19 | ||||
| 34 | 19 | ||||
| 28 | 18 | ||||
| 28 | 18 | ||||
| 24 | 17 | ||||
| 20 | 17 | ||||
| 20 | 17 | ||||
| 20 | 17 | ||||
| 19 | 16 | ||||
| 19 | 16 |
*Occurrence counts the number of network modules (by GO terms), in which Gene1 and Gene2 are significantly age co-expressed
Figure 2Group-based gene-gene correlation of “PTPN6, STAT5A” (A) and “ADORA2B, UNC13D” (B).
Figure 3Word-cloud plots of the functional annotation of age co-expressed genes in two tissues (A) adipose and (B) heart.
Functional enrichment of age co-expressed genes in adipose
| Module | FDR | |
|---|---|---|
| Immunity | 8.96E-50 | 1.32E-48 |
| ATP-binding | 1.45E-39 | 2.13E-38 |
| Nucleotide-binding | 1.69E-36 | 2.49E-35 |
| nucleotide phosphate-binding region:ATP | 1.02E-34 | 1.96E-33 |
| GO:0005886 plasma membrane | 9.65E-32 | 1.52E-30 |
| DNA damage | 1.14E-28 | 1.68E-27 |
| GO:0000122 negative regulation of transcription from RNA | 9.09E-29 | 1.81E-27 |
| Innate immunity | 3.75E-27 | 5.53E-26 |
| GO:0050852 T cell receptor signaling pathway | 9.88E-27 | 1.97E-25 |
| Kinase | 1.09E-25 | 1.60E-24 |
| GO:0005524 ATP binding | 2.38E-25 | 4.09E-24 |
| DNA repair | 7.78E-25 | 1.15E-23 |
| binding site:ATP | 1.23E-22 | 2.37E-21 |
| Cell cycle | 1.55E-21 | 2.29E-20 |
| Transferase | 2.90E-20 | 4.27E-19 |
| IPR011009:Protein kinase-like domain | 1.12E-19 | 2.01E-18 |
| IPR017441:Protein kinase, ATP binding site | 1.17E-19 | 2.10E-18 |
| Activator | 2.01E-19 | 2.96E-18 |
Figure 4Top 40 frequently enriched GO terms and KEGG pathways of age co-expressed genes across multiple tissues
Normalized log(FDR) is defined as [max(log(FDR))-log(FDR)]/[max(log(FDR))-min(log(FDR))]. A large “normalized log(FDR) ” indicates a more significantly enriched item.
Overlap between age co-expressed genes and GenAge genes
| Tissue | #Age | #GenAge | Background | #Overlap | Ratio* | |
|---|---|---|---|---|---|---|
| adipose | 2563 | 305 | 16516 | 155 | 50.82 | 5.21E-51 |
| Artery | 821 | 305 | 16096 | 56 | 18.36 | 4.45E-18 |
| heart | 2490 | 305 | 15721 | 137 | 44.92 | 8.02E-37 |
| lung | 1157 | 305 | 16853 | 80 | 26.23 | 3.68E-27 |
| muscle | 2025 | 305 | 15928 | 117 | 38.36 | 3.60E-33 |
| nerve | 769 | 305 | 16557 | 56 | 18.36 | 3.68E-20 |
| skin | 774 | 305 | 16733 | 47 | 15.41 | 5.91E-14 |
| thyroid | 1260 | 305 | 16737 | 69 | 22.62 | 1.09E-17 |
| whole blood | 1035 | 305 | 16025 | 69 | 22.62 | 1.09E-17 |
*Ratio is calculated as the number of overlap genes divided by that of the GenAge genes. #P-value is calculated by the one-sided Fisher’s exact test.
Figure 5A network view of key drivers of aging co-expressed genes for the module GO:0042098 “T cell proliferation”
In the PPI network. Red nodes represent key drivers and light green nodes represent other genes. Node size represents the rank of key drivers.
Predicting the anti-aging effect of metformin across tissues
| Tissue | Up-regulated | Tissue | Down-regulated | ||
|---|---|---|---|---|---|
| Rank* | Rank | ||||
| lung | 198 | 0.0022 | muscle | 63 | 0.0808 |
| artery | 1039 | 0.0540 | nerve | 130 | 0.0723 |
| lung | 416 | 0.0063 | |||
| adipose | 294 | 0.0001 | |||
*Rank is inferred based on p-values for all 4295 drugs with low p-value ranks first.